Trial Profile
Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, and 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2018
Price :
$35
*
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 12 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2017.